Ji-Hoon Son
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ji-Hoon Son has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Jinju Han
Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Korea
4 shared publications - Dayeon Kim
Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Korea
3 shared publications - Fred H. Gage
Laboratory of Genetics The Salk Institute for Biological Studies La Jolla California USA
3 shared publications - Geurim Son
Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Korea
3 shared publications - Hyunsu Do
Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Korea
3 shared publications - Insook Ahn
Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Korea
3 shared publications
Latest Publications
- Open Access
AGO1 in neural progenitor cells orchestrates brain development and sociability via LIN28A-REELIN axis
AGO1, an essential RNA binding protein (RBP) in RNA interference, is associated with autism spectrum disorder (ASD). However, the precise functions of AGO1 in brain development and related disorders remain largely unexplored. Here, we report the critical roles of AGO1 in neural progenitor cells (NPCs) in promoting sociability and shaping the structure of the developing brain. Ago1 knockout (KO) in the mouse brain leads to hyposociability, a characteristic symptom of ASD. In human forebrain organoids, AGO1 KO disrupts the formation of ventricle-like structures and delays cortical layer development. We discovered that AGO1 KO results in a loss of polarity in NPCs, which subsequently reduces neuronal development. These AGO1 KO phenotypes originate from the failure to suppress LIN28A in NPCs. AGO1 is primarily localized in the nucleus within NPCs and binds to the LIN28A promoter region, thereby inhibiting LIN28A transcription. We found that increased LIN28A in AGO1 KO NPCs reduces REELIN expression, a key regulator of brain development, by binding directly to the REELIN mRNA. The aberrant polarity phenotype in AGO1 KO NPCs was successfully ameliorated by either LIN28A knockdown or recombinant REELIN treatment. Collectively, our findings elucidate the intricate molecular mechanisms orchestrated by nuclear AGO1 in NPCs and underscores its pivotal roles in brain development, providing significant insights into ASD.
Open AccessAGO1 in neural progenitor cells orchestrates brain development and sociability via LIN28A-REELIN axis
AGO1, an essential RNA binding protein (RBP) in RNA interference, is associated with autism spectrum disorder (ASD). However, the precise functions of AGO1 in brain development and related disorders remain largely unexplored. Here, we report the critical roles of AGO1 in neural progenitor cells (NPCs) in promoting sociability and shaping the structure of the developing brain. Ago1 knockout (KO) in the mouse brain leads to hyposociability, a characteristic symptom of ASD. In human forebrain organoids, AGO1 KO disrupts the formation of ventricle-like structures and delays cortical layer development. We discovered that AGO1 KO results in a loss of polarity in NPCs, which subsequently reduces neuronal development. These AGO1 KO phenotypes originate from the failure to suppress LIN28A in NPCs. AGO1 is primarily localized in the nucleus within NPCs and binds to the LIN28A promoter region, thereby inhibiting LIN28A transcription. We found that increased LIN28A in AGO1 KO NPCs reduces REELIN expression, a key regulator of brain development, by binding directly to the REELIN mRNA. The aberrant polarity phenotype in AGO1 KO NPCs was successfully ameliorated by either LIN28A knockdown or recombinant REELIN treatment. Collectively, our findings elucidate the intricate molecular mechanisms orchestrated by nuclear AGO1 in NPCs and underscores its pivotal roles in brain development, providing significant insights into ASD.
- Open Access
- 22 August 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 30 (12) , 5833-5848
Differential effects of lithium on metabolic dysfunctions in astrocytes derived from bipolar disorder patients
Metabolic alterations have been observed in the brains of patients with bipolar disorder (BD), a neuropsychiatric disorder characterized by alternating episodes of mania and depression. However, the specific contributions of glial cells to these metabolic changes remain largely unknown. Here, we investigate the metabolic characteristics of induced astrocytes (iAstrocytes) derived from induced pluripotent stem cells of BD patients—classified by lithium responsiveness—and healthy controls. Transcriptomic analyses revealed dysregulated expression of genes associated with metabolic diseases in BD iAstrocytes. Compared to control iAstrocytes, BD iAstrocytes showed decreased mitochondrial respiration, increased glycolysis, and elevated lactate secretion, indicating impaired mitochondrial function. These defects were further supported by downregulation of oxidative phosphorylation complex proteins and decreased reactive oxygen species levels. Notably, BD iAstrocytes showed substantial lipid droplet (LD) accumulation, potentially as a consequence of disrupted metabolic homeostasis. Lithium treatment reduced LD levels in lithium-responsive (Li-R) iAstrocytes but failed to restore mitochondrial respiration or normalize lactate secretion. In co-culture with human neurons, lithium-nonresponsive (Li-NR) iAstrocytes exhibited enhanced uptake of neuron-derived lipids and selectively increased neuronal excitability. Metabolomic profiling revealed distinct metabolite signatures between Li-R and Li-NR iAstrocytes, suggesting lithium responsiveness as a key axis of metabolic heterogeneity. Together, our findings identify astrocyte-specific metabolic dysfunction as a hallmark of BD and reveal divergent roles of Li-R and Li-NR iAstrocytes in modulating neuronal function. LD accumulation in Li-NR iAstrocytes may serve as a functional readout for drug screening to identify alternative treatments for patients unresponsive to lithium.
- 22 August 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 30 (12) , 5833-5848
Open AccessDifferential effects of lithium on metabolic dysfunctions in astrocytes derived from bipolar disorder patients
Metabolic alterations have been observed in the brains of patients with bipolar disorder (BD), a neuropsychiatric disorder characterized by alternating episodes of mania and depression. However, the specific contributions of glial cells to these metabolic changes remain largely unknown. Here, we investigate the metabolic characteristics of induced astrocytes (iAstrocytes) derived from induced pluripotent stem cells of BD patients—classified by lithium responsiveness—and healthy controls. Transcriptomic analyses revealed dysregulated expression of genes associated with metabolic diseases in BD iAstrocytes. Compared to control iAstrocytes, BD iAstrocytes showed decreased mitochondrial respiration, increased glycolysis, and elevated lactate secretion, indicating impaired mitochondrial function. These defects were further supported by downregulation of oxidative phosphorylation complex proteins and decreased reactive oxygen species levels. Notably, BD iAstrocytes showed substantial lipid droplet (LD) accumulation, potentially as a consequence of disrupted metabolic homeostasis. Lithium treatment reduced LD levels in lithium-responsive (Li-R) iAstrocytes but failed to restore mitochondrial respiration or normalize lactate secretion. In co-culture with human neurons, lithium-nonresponsive (Li-NR) iAstrocytes exhibited enhanced uptake of neuron-derived lipids and selectively increased neuronal excitability. Metabolomic profiling revealed distinct metabolite signatures between Li-R and Li-NR iAstrocytes, suggesting lithium responsiveness as a key axis of metabolic heterogeneity. Together, our findings identify astrocyte-specific metabolic dysfunction as a hallmark of BD and reveal divergent roles of Li-R and Li-NR iAstrocytes in modulating neuronal function. LD accumulation in Li-NR iAstrocytes may serve as a functional readout for drug screening to identify alternative treatments for patients unresponsive to lithium.
- Open Access
- 25 October 2024
- Published by Springer Nature in Communications Biology
- Vol. 7 (1) , 1-14
miR-124 coordinates metabolic regulators acting at early stages of human neurogenesis
Metabolic dysregulation of neurons is associated with diverse human brain disorders. Metabolic reprogramming occurs during neuronal differentiation, but it is not fully understood which molecules regulate metabolic changes at the early stages of neurogenesis. In this study, we report that miR-124 is a driver of metabolic change at the initiating stage of human neurogenesis. Proteome analysis has shown the oxidative phosphorylation pathway to be the most significantly altered among the differentially expressed proteins (DEPs) in the immature neurons after the knockdown of miR-124. In agreement with these proteomics results, miR-124-depleted neurons display mitochondrial dysfunctions, such as decreased mitochondrial membrane potential and cellular respiration. Moreover, morphological analyses of mitochondria in early differentiated neurons after miR-124 knockdown result in smaller and less mature shapes. Lastly, we show the potential of identified DEPs as novel metabolic regulators in early neuronal development by validating the effects of GSTK1 on cellular respiration. GSTK1, which is upregulated most significantly in miR-124 knockdown neurons, reduces the oxygen consumption rate of neural cells. Collectively, our data highlight the roles of miR-124 in coordinating metabolic maturation at the early stages of neurogenesis and provide insights into potential metabolic regulators associated with human brain disorders characterized by metabolic dysfunctions.
- 25 October 2024
- Published by Springer Nature in Communications Biology
- Vol. 7 (1) , 1-14
Open AccessmiR-124 coordinates metabolic regulators acting at early stages of human neurogenesis
Metabolic dysregulation of neurons is associated with diverse human brain disorders. Metabolic reprogramming occurs during neuronal differentiation, but it is not fully understood which molecules regulate metabolic changes at the early stages of neurogenesis. In this study, we report that miR-124 is a driver of metabolic change at the initiating stage of human neurogenesis. Proteome analysis has shown the oxidative phosphorylation pathway to be the most significantly altered among the differentially expressed proteins (DEPs) in the immature neurons after the knockdown of miR-124. In agreement with these proteomics results, miR-124-depleted neurons display mitochondrial dysfunctions, such as decreased mitochondrial membrane potential and cellular respiration. Moreover, morphological analyses of mitochondria in early differentiated neurons after miR-124 knockdown result in smaller and less mature shapes. Lastly, we show the potential of identified DEPs as novel metabolic regulators in early neuronal development by validating the effects of GSTK1 on cellular respiration. GSTK1, which is upregulated most significantly in miR-124 knockdown neurons, reduces the oxygen consumption rate of neural cells. Collectively, our data highlight the roles of miR-124 in coordinating metabolic maturation at the early stages of neurogenesis and provide insights into potential metabolic regulators associated with human brain disorders characterized by metabolic dysfunctions.
- Open Access
Intragenic L1 Insertion: One Possibility of Brain Disorder
Long interspersed nuclear element 1 (LINE1, L1) is a retrotransposon comprising ~17% of the human genome. A subset of L1s maintains the potential to mobilize and alter the genomic landscape, consequently contributing to the change in genome integrity and gene expression. L1 retrotransposition occurs in the human brain regardless of disease status. However, in the brain of patients with various brain diseases, the expression level and copy number of L1 are significantly increased. In this review, we briefly introduce the methodologies applied to measure L1 mobility and identify genomic loci where new insertion of L1 occurs in the brain. Then, we present a list of genes disrupted by L1 transposition in the genome of patients with brain disorders. Finally, we discuss the association between genes disrupted by L1 and relative brain disorders.
Open AccessIntragenic L1 Insertion: One Possibility of Brain Disorder
Long interspersed nuclear element 1 (LINE1, L1) is a retrotransposon comprising ~17% of the human genome. A subset of L1s maintains the potential to mobilize and alter the genomic landscape, consequently contributing to the change in genome integrity and gene expression. L1 retrotransposition occurs in the human brain regardless of disease status. However, in the brain of patients with various brain diseases, the expression level and copy number of L1 are significantly increased. In this review, we briefly introduce the methodologies applied to measure L1 mobility and identify genomic loci where new insertion of L1 occurs in the brain. Then, we present a list of genes disrupted by L1 transposition in the genome of patients with brain disorders. Finally, we discuss the association between genes disrupted by L1 and relative brain disorders.